The percentage of T-ALL patients with elevated Notch pathway activity is higher than that of patients with somatic mutations in NOTCH1 and/or FBWX7, suggesting that other mechanisms might support NOTCH hyperactivation in T-ALL 21, 22. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.